It is vital patients understand the information provided by their medical team so they may make an accurate analysis and assessment of the treatment options that best suit their day-to-day life, age and occupation.


Healthy, balanced diet. Spread out over four meals per day. Use simple cooking techniques – steam, bake and grill – and avoid fried or heavily seasoned foods.

Bottle of water

Stay well-hydrated. Drink at least 1.5–2 L of fluids per day (water, fruit juices, infusions, etc.).

Two beer mugs crossed out indicating that alcohol is forbidden.

Evitar el consumo de alcohol.

Man running; regular physical exercise

Practice gentle exercise on a daily basis, outdoors if possible.

Family: father, mother and daughter

Take part in leisure activities, with family or friends where possible.

Two faces of the same person, one happy, the other one sad, symbolizing mood swings

Adopting a positive attitude helps overcome the process better.

Person seated cross-legged in yoga pose

Relaxation techniques tend to help patients maintain their emotional stability throughout the course of the disease. Try not to worry too much because stress and anxiety do not help the process.

Hasta hace pocos años los tratamientos para controlar el mieloma eran la quimioterapia, los esteroides (glucocorticoides), las terapias con dosis altas y el transplante autólogo (con las propias células madre de médula ósea). Desde hace unos años se han introducido nuevos tratamientos que están desplazando a la quimioterapia, o bien incorporándose a ella. Estos medicamentos incluyen la talidomida y sus derivados como la lenalidomida y la pomalidomida.

La introducción del bortezomib es un avance muy importante en el tratamiento del mieloma, con una nueva familia de fármacos llamada inhibidores de la proteosoma, que funciona de manera diferente a la talidomida.

También existen nuevos fármacos de esta familia como carfilzomib e ixazomib. Cada vez más hay nuevos fármacos para esta enfermedad, incluyendo anticuerpos monoclonales contra las células malignas, que se van incorporando a las diferentes etapas de la enfermedad.

Although other treatments are available for multiple myeloma, chemotherapy is one of the most common. It is generally administered intravenously, but in some cases it may be taken orally.

Chemotherapy inhibits the growth of cells in the process of division. It affects both tumour and healthy cells which is what causes the adverse effects or side effects associated with the treatment.

Chemotherapy may be administered in combination with other treatments, for example immunotherapy. The number of cycles mainly depends on the patient’s age, the tumour stage and their overall state of health. Various tests are conducted after each chemotherapy cycle to evaluate the treatment’s effectiveness.

Tired, sweating man

Fatigue. This is one of the most common treatment-related complications. Discuss it with your doctor because there are several options available to treat the causes and help you feel better.

Blood test tube with a low red blood cell count or anemia

Response associated with a low blood cell count. The lack of red blood cells produces low levels of haemoglobin in blood; this subsequently causes anaemia leading to fatigue and weakness. A low white blood cell count increases the susceptibility to infections, while a low platelet count may mean the patient bruises and bleeds more easily.

Numbness or tingling in hands and feet

Side effects. Certain drugs, such as thalidomide and bortezomib, present special complications as they may damage nerves in the hands and feet (neuropathy).

Palliative treatment is the normal option when the disease cannot be totally eliminated. It is designed to relieve the symptoms of multiple myeloma and improve the patient’s quality of life. 

What is Cancer?

General information about Cancer

Read more

Substantiated information by:

Carlos Fernández de Larrea Rodríguez
Gloria Garcia Barriga

Published: 20 February 2018
Updated: 20 February 2018

The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.


Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.